Colorectal Cancer News & Features

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

Not Enough Americans Being Screened for Cancer

January 26, 2012

Rates of cancer screening in the United States are short of Healthy People 2020 targets for breast, cervical, and colorectal cancer screening
 

Study demonstrates mortality disparity among colorectal cancer patients

Delicia Honen Yard January 11, 2012

Concerted efforts to prevent or detect colorectal cancer at earlier stages in black patients could improve the worsening black-white disparities uncovered in a recent analysis.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

New Predictors of Treatment Response Identified for CRC

January 04, 2012

Hypermethylation of TFAP2E associated with chemoresistance in colorectal cancer
 

Cancer-Related Mortality Continues to Decrease

January 04, 2012

Overall cancer rates have decreased for men and remained stable for women, but mortality from cancer has declined for both sexes, according to a report from the American Cancer Society.
 

Gene sequencing can match patients to best cancer trials

Delicia Honen Yard December 15, 2011

Identifying the "mutational landscape" of a person's cancer is a promising method of determining which trials are best-suited to the patient's particular case.
 

Diabetes drug helps prevent growth of breast cancer cells

Delicia Honen Yard December 09, 2011

Metformin, a widely used agent in the treatment of type 2 diabetes, stopped a number of natural and man-made chemicals from stimulating the growth of breast cancer cells.
 

CT colonography raises screening rates, but colonoscopy finds more advanced neoplasia

Delicia Honen Yard December 01, 2011

Offering CT colonography improved participation in colorectal cancer screening by more than 50% compared with colonoscopy, but colonoscopy identified significantly more advanced neoplasia.
 

LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication

Delicia Honen Yard November 18, 2011

The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
 

Colorectal Cancer Clinical Trials

Clinical Trial: Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba

Clinical Trial: Colorectal Cancer Detection by Means of Optical Fluoroscopy

Clinical Trial: Longitudinal Study of Symptoms in Colorectal Cancer

Clinical Trial: Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III

Clinical Trial: Cytokine Changes After Colorectal Cancer Resection

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets

 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions